Dyslipidemia in Diabetes: When and How to Treat?

Ronald B Goldberg

doi:10.1016/j.ecl.2022.02.011

Dyslipidemia in Diabetes: When and How to Treat?

Endocrinol Metab Clin North Am. 2022 Sep;51(3):603-624. doi: 10.1016/j.ecl.2022.02.011. Epub 2022 Jul 4.

Author

Ronald B Goldberg¹

Affiliation

¹ Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, 1450 Northwest 10th Avenue, Miami, FL 33136, USA. Electronic address: rgoldber@med.miami.edu.

PMID: 35963631
DOI: 10.1016/j.ecl.2022.02.011

Abstract

Elevated triglyceride and reduced high-density lipoprotein cholesterol (HDL-C) are common in type 2 diabetes, but increased atherogenic particles and dysfunctional HDL are demonstrable in both types 1 and 2 diabetes, contributing to a two-fold increase in atherosclerotic cardiovascular disease (ASCVD). ASCVD risk accelerates with diabetes duration and severity, aging, risk factors, and risk enhancers. Using statins or other LDL-C-lowering agents if needed in adults with intermediate or greater degrees of risk is recommended. Although hypertriglyceridemia enhances risk, most guidelines do not recommend fibrates or omega 3 fatty acid for risk reduction except for icosapent ethyl in patients with ASCVD.

Keywords: Diabetes; Dyslipidemia; Management; Pharmacotherapy.

Publication types

Review

MeSH terms

Adult
Atherosclerosis* / etiology
Atherosclerosis* / prevention & control
Cardiovascular Diseases* / etiology
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Dyslipidemias* / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Hypertriglyceridemia* / complications

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors